Hit enter to search or ESC to close
IDEAYA Biosciences
  • Company
    • Company Overview
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Partners
  • Science
    • Introduction
    • Biomarker Translational Approach
    • Targeted Therapies
    • Synthetic Lethality
    • Synthetic Lethality Target Discovery Platform
    • References
  • Pipeline
    • Overview
    • PKC (IDE196)
    • Synthetic Lethality Pipeline
  • Newsroom
  • Investors
    • Overview
    • Stock Information
      • Stock Quote/Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
      • Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Governance Highlights
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact
    • General Inquiries
    • Partnership Inquiries
    • News Alerts
IDEAYA Biosciences
In the News

Ideaya Biosciences Launches With $46M Series A [via The Wall Street Journal]

By IDEAYA Biosciences May 4, 2016 January 10th, 2018 No Comments

Ideaya Biosciences Launches With $46M Series A [via The Wall Street Journal]

https://www.ideayabio.com/wp-content/uploads/2018/01/WallStreetJournal_IDEAYASeriesA_05_04_16.pdf

© 2019 IDEAYA Biosciences | Terms of Use | Privacy Policy

  • Company
    • Company Overview
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Partners
  • Science
    • Introduction
    • Biomarker Translational Approach
    • Targeted Therapies
    • Synthetic Lethality
    • Synthetic Lethality Target Discovery Platform
    • References
  • Pipeline
    • Overview
    • PKC (IDE196)
    • Synthetic Lethality Pipeline
  • Newsroom
  • Investors
    • Overview
    • Stock Information
      • Stock Quote/Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
      • Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Governance Highlights
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact
    • General Inquiries
    • Partnership Inquiries
    • News Alerts